Weight-loss medicines: Biocon eyes a $100 billion jackpot with weighty pivot

Weight-loss drugs: Biocon Ltd. is shifting focus to anti-obesity therapies as patents for key medications expire, leading to a surge in generic supply. The Bengaluru-based company secured UK approval for the first generic version of liraglutide injectible, positioning itself as a leader in this evolving market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BeadmRQ
via IFTTT